Shift of Colorectal Procedures to ASCs Signals Growing Role for Commercial Analytics

A LinkedIn post from AcuityMD highlights newly released internal data indicating a notable shift in where endoscopic colorectal procedures are performed in the U.S. The post cites nearly 9 million such procedures at ambulatory surgery centers, or ASCs, in 2024, describing this as a roughly 50% increase since 2018 and suggesting that ASCs now handle the majority of these procedures.

According to the post, ASCs are portrayed as materially less expensive than hospitals, with referenced cost reductions of 60% or more, potentially improving affordability and access to screening for colorectal disease. The content also links earlier and more accessible screening to earlier detection of colorectal cancer and other gastrointestinal conditions, implying a possible public-health benefit alongside the procedural shift.

For investors, the post frames this trend as a commercial signal for MedTech companies, emphasizing that procedure volumes are moving away from hospitals toward ASCs. It suggests that MedTech commercial teams that do not actively track this migration may lose visibility into where demand is growing, underscoring the importance of data and analytics tools such as those AcuityMD markets.

The referenced report, which the post promotes via a link, appears positioned as a resource to understand these site-of-care trends and to help sales organizations target the “right physicians” more effectively. If accurate and widely adopted, such insights could support AcuityMD’s value proposition in commercial intelligence for medical device companies and potentially enhance its competitive standing in the healthcare data and software segment.